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Osteoclast subsetThe multinucleated osteoclast has a unique function: degradation of mineralized tissues. It is generally taken
that all osteoclasts are alike, independent of the skeletal site where they exert their activity. Recent data,
however, question this view as they show that osteoclasts at different bony sites appear to differ, for example
in the machinery responsible for resorption. Support for the notion that there may be heterogeneity in
osteoclasts is obtained from studies in which osteoclast activity is inhibited and from observations in
osteopetrosis and inﬂammatory bone conditions. In this review we discuss the available evidence and
propose the existence of bone-site-speciﬁc osteoclast heterogeneity.
© 2009 Elsevier B.V. All rights reserved.1. General introductionOsteoclasts are deﬁned as cells that can break down bone, theword
being derived from the Greek oston bone and klastos, broken. In older
literature a range of additional terms has been used to name cells that
break down other types of mineralized matrices, for example:
“chondroclasts” for cells that break down mineralized cartilage and
“dentinoclasts” for cells that break down mineralized dentine. More
recently, osteoclast has become the common term to denote any cell
that has the capacity to break downmineralized matrices, as it is clear
that in the growth plate the same cell can frequently be found to resorb
both bone and cartilage simultaneously (Fig. 1) and cells taken from
bone can easily resorb dentine as many laboratory studies indicate
(Fig. 2). While undoubtedly osteoclasts can attack a wider range of
matrices than their name suggests, recent studies have raised some
new questions about the possible existence of different types of
osteoclasts at different bone sites. In this review we discuss the avai-
lable evidence, most of which comes from the study of osteopetrosis
and from inﬂammatory bone conditions. It remains unclear whether
heterogeneity in this cell type is the result of differential regulation in
different bone sites. The implications of the possible presence of site-
speciﬁc osteoclasts may be signiﬁcant, especially when considering
novel treatment options to inhibit resorption.31 20 4448683.
ll rights reserved.2. Osteopetrosis and tooth eruption
As much evidence pointing to the possible existence of different
subsets of osteoclasts comes from observations in osteopetrosis and
especially from differences in osteoclast activities between the axial
skeleton and the head region, as evidenced by (lack of) tooth eruption,
we will ﬁrst discuss osteopetrosis and pay some attention to the
events that lead to tooth eruption.
2.1. Osteopetrosis
Osteopetrosis is deﬁned as a disease characterized by a general
increase in bone mass caused by inactivity, or absence of osteoclasts.
While in osteopetrosis the bone mass is high, the bone itself is brittle
and fractures are common. This differentiates the condition from
other high bone mass disorders caused primarily by overactivity of
osteoblasts, such as for example sclerosteosis or Van Buchem's disease
[1] where bones are very strong.
Osteopetrosis is genetically heterogeneous with autosomal domi-
nant and recessive forms. There is a wide spectrum of severity in the
human condition with the most severe forms caused by autosomal
recessive inheritance. Much has been learned in the past 25 years from
the study of spontaneous mutations in animals that lead to
osteopetrosis and more recently the genes causing such phenotypes
have been identiﬁed and in most instances conﬁrmed as causes of
human osteopetrosis. In addition targeted gene deletion, or gene
Fig. 1. (A) Electron micrograph of an osteoclast resorbing both calciﬁed cartilage (Ca)
and bone (Bo). Note the extensive rufﬂed border (RB), the site where the actual
resorption occurs, and the sealing zone (SZ), the site where the osteoclast is attached to
the bone/cartilage surface. N: nucleus. (B) Schematic drawing of an osteoclast in which
the most important membrane domains are shown. The osteoclast is attached to the
bone by the sealing zone (SZ), in the centre of this area resorption occurs underneath
the rufﬂed border (RB), following resorption fragments are transported through the
osteoclast to the functional secretory domain (FSD).
Fig. 2. (A) Electron micrograph (TEM) of an osteoclast seeded on a dentine slice.
Resorption of the dentin occurs at the rufﬂed border (RB) and the cell is attached to the
dentine by a sealing zone (SZ). Note the numerous small cellular extensions at the
membrane opposite to the rufﬂed border, the functional secretory domain (FSD). N:
nucleus. (B) Scanning electron micrograph of an osteoclast (OC) seeded on a slice of
dentine. The osteoclast has resorbed part of the surface as shown by the presence of
resorption lacunae, the pits.
Fig. 3. (A) Electron micrograph of an osteoclast resorbing bone. The rufﬂed border (RB)
is shown at a higher magniﬁcation in (B) SZ: sealing zone.
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additional osteopetrotic phenotypes and again pointed to some of the
genes that are mutated in the human condition. Several reviews have
recently summarized the remarkable progress made in this ﬁeld and
the reader is referred to those for detailed information [2,3]. Not only
have these studies helped to understand osteopetrosis, they have also
provided information about the essential genes necessary for
osteoclast development and function. We now know that osteoclast
development requires two growth factors, M-CSF, which stimulates
the proliferation of osteoclast precursors, and RANKL, which promotes
differentiation towards mature osteoclasts. Absence of either growth
factor, or its receptors leads to severe osteopetrosis in rodents with
lack of osteoclast formation [4–8]. Loss-of-function mutations in
RANKL, or its receptor RANK on the osteoclast, have now also been
identiﬁed in osteoclast-poor cases of human osteopetrosis [9,10].
More commonly however, osteopetrosis is caused by loss-of-function
mutations in genes essential for osteoclast function. The genes
identiﬁed so far in this subgroup are all involved in generation and
transport of protons and the vesicles that contain them [11], to the
rufﬂed border, the highly folded membrane domain facing the surface
of the mineralized matrix the cell is resorbing (Fig. 3).
A common feature in these cases of osteopetrosis is that osteoclasts
form, frequently in relatively high numbers (Fig. 4) and attach to the
bone surface with a sealing zone, but that they do not form a rufﬂed
border. The rufﬂed border is a unique membrane structure in osteo-clasts and is the site where the cells lower the pH of the extracellular
resorption compartment underneath by secreting protons. This
activity results in the dissolution of the mineral (hydroxyapatite),
thus exposing organic matrix components, such as type I collagen. A
concomitant release of proteolytic enzymes, in particular the cysteine
proteinase cathepsin K, results in breakdown of the organic matrix.
The V-ATPase, the proton pump essential for the release of H+ in the
resorption area, is localized in the membrane of acidic vesicles in the
osteoclasts and inserted into the rufﬂed border membrane when the
osteoclast polarizes to start resorption. In the absence of functioning
V-ATPase proton secretion and hence mineral dissolution are com-
pletely compromised [12]. To balance the charge of ions across the
membrane, chloride is released concomitantly in the resorption
lacuna through the use of a chloride channel, ClC-7 [13], which is
also present in the membrane of acidic vesicles and inserted in the
rufﬂed border membrane when resorption starts. Two recently
identiﬁed proteins, Plekhm1 and Ostm1, appear to facilitate the
transport of the acidic vesicles to the rufﬂed border, in case of Ostm1,
Fig. 4. Light micrograph of numerous osteoclasts (OC) present in the bone of an
osteopetrosis patient. The osteoclasts are present but do not have the capacity to resorb
the bone and/or calciﬁed cartilage.
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remain to be elucidated, but loss-of-function mutations in these
proteins lead to osteopetrosis in rodents and in man [15,16]. The
generation of H+ in osteoclasts is dependent on the activity of the
enzyme carbonic anhydrase II, which generates a proton and a
bicarbonate ion from carbon dioxide and water. Mutations leading to
reduced activity of this enzyme compromise osteoclast activity [17].
The bicarbonate is removed from the cytoplasm by exchange with
chloride, facilitated by the anion exchanger AE2, which is active at the
basolateral membrane of the osteoclast (Jansen et al., manuscript
submitted).
In the case of malfunctioning of V-ATPase, ClC-7, CAII, Plekhm1,
Ostm1, or AE2, the osteoclast is unable to form a rufﬂed border. This
contrastswith the situation inwhich theproteolytic enzymecathepsinK
is inactive or not expressed. In such cases osteoclasts do form a –
sometimes structurally abnormal – rufﬂed border and secrete acid, but
they are unable to digest the organic bone matrix. A characteristic
feature in bone biopsies of patients in which cathepsin K is not
functioning normally, a disease called pycnodysostosis, is the huge
amount of non-digested demineralized bone matrix adjacent toTable 1
Mutation/gene defect Disease Skull/jaw bones
Sh3bp2−/− Cherubism Affected (osteonecros
Cathepsin K−/− Pycnody sostosis Unaffected
Connexin 43−/− Affected
TRAF6−/− Unaffected
MMP-2−/− Affected
NFATc1−/− Unaffected
Ihh−/− Unaffected
HIFα−/− Unaffected
AE2−/− Unaffected
Differences between osteoclasts
TRACP expression ++++
MMPs used for resorption ++
CPs used for resorption +
Size of osteoclasts ++++
Experimental approach
Sympathectomy Affected
Pressure induced remodeling Very sensitive
Remodeling Relatively fast
PTH application Unaffected
OPG overexpression Unaffected osteoclasto
Bisphosphonate application Paget's disease of bone Limited effect on bone
PGE2 application Unaffected
Marrow cells Fast proliferation
MMP-resistant bone collagen Very thickpolarized resorbing osteoclasts [18,19]. In addition, the endosomal
compartmentof these cells contains high amounts of non-digestedbone
collagen ﬁbrils; a phenomenon frequently seen in ﬁbroblasts but only
ever seen in osteoclasts from patients with pycnodysostosis [18].
2.2. Tooth eruption in osteopetrosis
Tooth eruption is critically dependent on osteoclast activity in the
jaw to create a path for the developing tooth through the alveolar
bone to the oral cavity. A characteristic feature of osteopetrosis is
therefore the absence or severe delay in tooth eruption, something
that, in rodent studies, is usually the ﬁrst sign an animal is
osteopetrotic (as reﬂected in strain names such as “toothless” or
“incisor absent”). It is clear from histological and radiological studies
that tooth germs are present in the jaw in all types of osteopetrosis
and it has been shown that overcoming the defect causing osteoclast
dysfunction may rescue tooth eruption (reviewed in [20]). However,
as we will see further below, in some cases of osteopetrosis tooth
eruption does not strictly correlate with osteoclast activity in other
parts of the skeleton. A complication in the interpretation of some of
these studies is the fact that only a small window of time exists for
rescue of tooth eruption (see [20]).
The precise sequence of events leading to tooth eruption has been
reviewed previously and many of the factors regulating bone
remodeling are identiﬁed as important in this process [21]. The
same factors are involved in the shedding of deciduous teeth and the
replacement by permanent teeth, a process even more remarkable as
it involves resorption of the root of the deciduous tooth by osteoclasts
while also creating the eruption pathway for the underlying
permanent replacement [22]. In human patients with osteopetrosis
it is often during this second wave of tooth eruption when problems
occur and supernumerary teeth may be seen, or alternatively lack of
eruption of the permanent teeth.
Important in the context of this discussion is the fact that tooth
eruption requires time-limited recruitment of osteoclast precursors,
their local formation and subsequent activation. Not only diseases
affecting osteoclast differentiation, or osteoclast function therefore
can result in reduced or delayed tooth eruption, but also conditions in
which osteoclast precursor recruitment is insufﬁcient. This occurs in
patients with cleidocranial dysplasia (CCD), who have a mutation inLong bones
is) Unaffected [80]
Affected [49,81]
Unaffected [82]
Affected [83]
Unaffected [84]
Affected [85]
Affected [27,86]
Affected [29]
Affected
++ [50,52]
− [19,44,45]
+++ Idem
++ [87]
Unaffected [36–38]
Less sensitive [39]
Relatively slow [33]
Affected [35,88]
genesis Affected osteoclastogenesis [26]
turnover markers Normalization of bone turnover markers [89]
Stimulated growth [34]
Slow proliferation [90]
Unaffected [44]
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often suffer from problems with tooth eruption and supernumerary
teeth. While Runx2 has an important role in tooth formation, as it is
expressed in odontoblasts and cementoblasts, the main reason for the
problems in the CCD patients appears to be the reduced synthesis of
RANKL and osteoclast precursor recruitment factors, such as M-CSF
and MCP-1, by immature osteoblasts in the alveolar bone [23].
2.3. Bone-site-speciﬁc types of osteopetrosis
In addition to the systemic forms of osteopetrosis (i.e. where the
osteoclast abnormalities are found throughout the body), a number of
osteopetrotic phenotypes have been identiﬁed in transgenic or
knockout mice in which osteopetrosis is bone-site speciﬁc (see
Table 1). In these mouse models the sclerotic skeleton does not
necessarily correlate with lack of tooth eruption, pointing to different
osteoclast activities in the jaw, or even the whole head region, and the
rest of the skeleton. For example, in RANKL−/− mice, that lack an
essential osteoclast differentiation factor, a general osteopetrotic
phenotype is seen. However, when Odgren et al. [24] performed
rescue experiments with CD4-driven RANKL they noticed that the
teeth did not erupt in the rescued mice. Their ﬁndings indicated
continued osteoclastic underactivity in the jawwhile at the same time
osteopetrosis in the long boneswas resolved, indicating normalization
of osteoclast function. These ﬁndings suggested that osteoclasts at
different bone sites respond differently to rescue by RANKL presented
by CD4-positive immune cells. Similar ﬁndings have been reported for
rescue of osteopetrosis in the op/opmouse usingM-CSF. Interestingly,
the op/op sclerotic phenotype resolves with age, but tooth eruption
never spontaneously occurs. Systemic administration of M-CSF was
able to rescue tooth eruption, but only if given before a critical time
window [25]. While this indicates that timing of osteoclast recruit-
ment is essential in the jaw, persistent lack of tooth eruption in the
presence of normal osteoclastic bone remodeling elsewhere in the
skeleton does suggest site-speciﬁc differences in the ability of a bone
tissue to recruit and activate osteoclasts. Clearly, the jaw and in
particular the dental follicle and roots of permanent teeth are a
protected site where in general osteoclast activity is suppressed. The
opposite situation to that seen in the op/op mouse or the RANKL−/−
mouse, is found in mice over-expressing the RANK decoy molecule
OPG. Here, tooth eruption occurs as normal indicating that the
osteoclasts in the alveolar bone function normally. Osteoclasts in the
periosteum of long bones are equally active, but those in trabecular
bone were inactive [26].
The anion exchanger-2 (AE2) has several isoforms. Recently it was
shown that mice deﬁcient for three of its ﬁve isoforms have normal
tooth eruption and normal resorption in skull bone, whereas long
bones are severely osteopetrotic. In line with these observations,
osteoclasts in the skull displayed a normal rufﬂed border, whereas this
membrane structure was absent in long bone osteoclasts. Subse-
quently it was shown that the osteoclasts in the head region, but not
those in the long bones, used a sodium transporter (SLC4a4) in
addition to AE2 to transport chloride and/or bicarbonate across the
membrane and could therefore compensate for the absence of AE2
(Jansen et al., FASEB J. in press). Together these observations clearly
indicate that bone-site-speciﬁc differences in osteoclastic activity
exist. In the following sections, we will discuss possible explanations
for the presence of site-speciﬁc regulation of bone resorption and pay
particular attention to the possibility that such differences may arise
from differences in osteoclasts themselves.
3. Different bones, different cells and different responses?
How can bone-site-speciﬁc differences in osteoclastic activity be
explained? Two possible explanations spring to mind. Firstly, it is
possible that the composition of the various skeletal bones is differentand therefore requires osteoclasts with different activity proﬁles.
Alternatively, it is possible that osteoclasts at different skeletal sites
are intrinsically different. In both scenarios the result is the presence
of osteoclasts which are best equipped (“the ﬁttest”) for their role in
their unique local microenvironment. To further discuss these two
scenarios we ﬁrst touch upon the two ways in which bone formation
occurs during embryogenesis.
The bones of our skeleton are formed either by endochondral or by
intramembranous ossiﬁcation. Endochondral ossiﬁcation, which is
characterized by the initial formation of a cartilagemodel of the future
bone, the bone anlage, which is gradually replaced by bone, is the
process responsible for formation of the majority of the bones of the
skeleton. Other bones (e.g. skull, jaws, and scapula) are formed by
direct bone deposition in a condensed connective tissue, gradually
replacing this connective tissue by bone. Long bones are considered to
be formed by a combination of endochondral and intramembranous
bone deposition. Part of the bone shaft (diaphysis) is formed by
intramembranous ossiﬁcation while he the rest is formed by endo-
chondral ossiﬁcation. Given the different ways of bone formation it
may not be surprising that cells in different skeletal sites have
different properties. We will ﬁrst turn our attention to some of these
as they relate to bone formation, i.e., osteoblasts and the matrix they
produce, then to evidence for a different regulation of cells at different
sites, before summarizing the evidence for intrinsic differences in
osteoclasts at different sites.
3.1. Bone-site-speciﬁc differences in the formation of bone
Endochondral bone formation has been shown by Chung et al. [27]
and Long et al. [28] to critically depend on Indian hedgehog (Ihh)
expression and signaling. By contrast, lack of Ihh did not affect the
presence or activity of osteoblasts at sites of intramembranous bone
formation.
Hypoxia-inducible factor α (HIFα) similarly proves to be essential
for osteoblastic activity during endochondral bone formation but not
during intramembranous bone formation [29]. Angiogenesis proved
essential for the remodeling of long bones whereas this was found less
important for remodeling of intramembranous bone [29].
Together these data suggest considerable bone-site-speciﬁc diffe-
rences in regulation of osteoblast activity. This, as we will see later on,
results in differences in the matrices they produce. It seems that the
situation in bone may be analogous to that in hyaline cartilage at
different anatomical sites where signiﬁcant differences in function
and in composition are found, for example between cartilage in the
growth plate and articular cartilage.
3.2. Bone-site-speciﬁc differences in matrix composition
A different mode of ossiﬁcation may be expected to result in
compositional differences of the matrix and its subsequent minera-
lization. This indeed appears to be the case. Not only the amount of
collagen and non-collagenous proteins differs considerably between
skull and long bone also the level of collagen cross-linking was shown
to be greatly diverse [30]. These differences are considered to be
important for the mechanical properties and mechanical demands
made on the different bones. After all each bone has its own unique
function in providing support and/or protection of speciﬁc parts of the
body.
Each of the different types of bone appears to have its own unique
osteoinductive components [31,32]. Extracts of long bone can induce
formation of cartilage as an intermediate step in the process of
formation of bone. Extracts of intramembranous bone do not seem to
have this capacity [31].
In addition to differences in the composition, abundant data
indicate differences in bone remodeling times. Remodeling of calvaria
bone is much slower than the remodeling of long bones [33]. Whether
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osteoclastic activities, to differences in the proportion of cortical or
trabecular bone, or to differences in the neuronal and/or hormonal
modulation is still a matter of debate.
3.3. Bone-site-speciﬁc differences in hormonal responses
A series of elegant experiments has shown bone-site-speciﬁc
responses to compounds such as prostaglandin E2 (PGE2) and para-
thyroid hormone (PTH). In 1998, Suponitzky and Weinreb [34]
demonstrated that systemic in vivo application of PGE2 to rats resulted
in an increased bone formation in long bones without affecting calvaria
bones. Also systemic injection of PTH had an anabolic effect on long
bones but not on those of the skull [35]. Hens need to release large
amounts of calcium from their skeleton during their egg-laying period
andhaveaveryhighosteoclastic activity in speciﬁc bones, themedullary
bones, whereas skull bones are spared. Systemic hormones regulate
calcium release through regulating medullary osteoclast activity, thus
indicating that not all osteoclasts respond similarly to circulating
hormones. It remains to be seen, however, whether in this case
the osteoclast or the osteoblast is the cell responsible for the bone-
site-speciﬁc effect as osteoblasts are the cells expressing PTH receptors.
3.4. Bone-site-speciﬁc differences in neuronal response
Sympathectomy results in an increased resorption of intramem-
branous bone whereas it does not affect resorption of endochondral
bone [36,37]. This resorption-stimulating effect was noted in bones of
the middle ear and in mandibular bones, but not at other skeletal sites
[38], leading the authors to suggest that blockage of sympathic nerves
increases resorption whereas blockage of sensoric nerves decreases
resorption. These data strongly suggest bone-site-speciﬁc differences
in responses due to different neuropeptides to which the bone cells
(osteoclasts and/or osteoblasts) respond [38].
3.5. Bone-site-speciﬁc differences in mechanically-induced responses
Different bone types have different turnover rates, which are
largely dependent on the different mechanical strains experienced by
the tissue. According to Chole [39] intramembranous bone is more
sensitive to pressure-induced remodeling than endochondral bone.
While the precise mechanism underlying mechanically-induced
remodeling is not yet clear, we know that the osteocyte network is
critically important in regulating bone formation and resorption.
Osteocytes sense differences in strain and subsequently send signals
(e.g. nitric oxide, PGE2, sclerostin) to bone surface-associated cells,
such as bone lining cells, osteoblasts and osteoclasts to stimulate or
block their activity, thus modulating bone remodeling [40,41].
Given the differences in remodeling rate between the various bone
types, it is of interest to note that osteocytes in bones of the skull differ
from those in long bones. Vatsa et al. [42] recently showed that skull
osteocytes were rounder than those of the long bones. Since a round
cell appears to be more sensitive to mechanical signals than a ﬂat cell
[43], skull osteocytes may respond more easily to the lower me-
chanical strains in the skull. These observations could help to explain
why differences exist in remodeling rates in different types of bone.
3.6. Bone-site-speciﬁc differences in osteoclasts
There is a substantial body of evidence to suggest considerable
differences between osteoclasts at various bone sites. Already 10 years
ago, in 1999, we showed that calvaria osteoclasts differ from those
present in long bones with respect to the proteolytic enzymes used for
bone matrix digestion [44]. Long bone osteoclasts synthesize
primarily cysteine proteinases (especially cathepsin K), whereas cal-
varia osteoclasts additionally employ matrix metalloproteinases(MMPs). In a more detailed follow-up study we showed that the
different osteoclast populations also synthesized and used additional
cysteine proteinases [19], although the nature of these enzymes still
needs to be established. In line with these ﬁndings is the study by
Shorey et al. [45] who showed that osteoclasts, present in the
intramembranous scapula, also use MMPs, in addition to cysteine
proteinases, to digest organic bone matrix, thus generalizing the
concept that intramembranous bones are degraded not only by
cysteine proteinases but also by osteoclastic MMPs.
This is a departure from the general notion that cathepsin K is
essential for the digestion of organic bone matrix by osteoclasts [46].
We have already mentioned the disease pycnodysostosis, caused by
loss-of-function mutations in the cathepsin K gene [47] where
osteoclasts are able to demineralize bone, but cannot degrade the
organic matrix. Generation of cathepsin K deﬁcient mice [48,49]
conﬁrmed the importance of cathepsin K in osteoclast-mediated bone
degradation. However, interestingly, these studies also showed that
absence of cathepsin K affected remodeling of calvaria bone much less
than that of long bones, clearly pointing to differential use of cathepsin
K by osteoclasts at different bone sites.
Another remarkabledifferencebetweenosteoclast populations is the
expression level of the enzyme tartrate resistant acid phosphatase
(TRACP). Although this enzyme is highly expressed by multinucleated
osteoclasts in all types of bone, expression levels aremuch higher (up to
25-fold) in calvaria osteoclasts compared to long bone osteoclasts [50].
The higher expression in calvaria osteoclasts seems to relate to the
important role of TRACP in digestion of the non-collagenous protein
osteopontin [51] as in TRACP-deﬁcient mice higher levels of non-
digested osteopontin are found adjacent to calvaria osteoclasts, com-
pared to long bone osteoclasts [50]. In addition to differences in TRACP
expression between different bone sites, osteoclasts also differed in
TRACP expression within the same type of bone [52]. A higher level of
TRACP expression was found in osteoclasts in the proximal epiphysis
(resembling the “calvaria osteoclast phenotype”) compared with
trabecular osteoclasts [52]. Theﬁndings that characterize the osteoclasts
at different bone sites are summarized in Fig. 5.
Finally, several studies have shown heterogeneity in osteoclasts
with respect to their size [53–55]. Several groups demonstrated that
small osteoclasts showed less resorption [53,56] and adhered more
strongly to prothrombin and thrombin than large osteoclasts.
4. How are bone-site-speciﬁc osteoclasts formed?
4.1. Different osteoclasts due to different osteoblasts?
The osteoblast or, more precisely, the bone lining cell, an osteoblast-
lineage cell that does not produce osteoid, plays a crucial role in the
generation of osteoclasts. It recruits osteoclast precursors to the resorp-
tion site by the release of chemokines [57]. Following this chemoattrac-
tion the osteoclast precursors attach to the bone lining cells via ICAM-1/
VLA interaction [58] and this allows the receptor RANKexpressed by the
osteoclast precursors to bind its ligand RANKL expressed by the lining
cell. This results in the priming of the precursor to start differentiation
into an osteoclast expressing characteristic features such as TRACP
activity, and receptors for calcitonin and vitronectin. Subsequently, the
bone lining cells move out of the way thus exposing the bone surface to
which the primed precursors migrate and where they complete
maturation and fusion [59].
The ratio of RANKL with its decoy receptor OPG is essential for
osteoclastogenesis. When Odgren et al. analyzed the effect of trans-
genically induced RANKL expression in RANKL deﬁcient mice, they
noted normalization of osteoclast formation in long bones but not in
the jaw and concluded that “failure of bone resorption in the jaws is
highly site-speciﬁc” [24]. Since RANKL is highly expressed by bone
lining cells [60,61], this ﬁnding supports the notion that bone-site
speciﬁcity exists with respect to expression of RANKL. In keeping with
Fig. 5. Schematic presentation of known and putative differences between osteoclasts
present in the skull and in long bone. Skull osteoclasts use MMPs and cysteine pro-
teinases (among which cathepsin K) for resorption, whereas long bone osteoclasts use
primarily cysteine proteinases. Skull osteoclasts are bigger and express a higher level of
TRACP. The anion exchanger-2 (AE2) is essential for resorption by long bone osteoclasts,
but less important for resorption by skull osteoclasts. The latter cells express the sodium
transporter Slc4a4, which seems to compensate for the loss of AE2. Skull osteoclasts
may use different signaling pathways than through TRAF6 and NFATc1, since skull bone
is not affected in TRAF6 and NFATc1 null mutant mice.
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genesis at the endosteal and trabecular bone sites, but not in
periosteum or the jaw where osteoclasts are formed unhindered
[26]. In line with a bone-site-speciﬁc response of bone lining cells/
osteoblasts is the response to the hormone PTH. Several studies have
shown that whereas the metaphysis is highly sensitive to this
hormone the skull bone is hardly responsive (see [35]). Collectively,
these data strongly suggest considerable differences between osteo-
blasts/bone lining cells in different bones. Whether such different
populations of osteoblasts result in the formation of phenotypically
different osteoclasts remains to be demonstrated.
4.2. Different osteoclasts due to differences in substrate?
The composition of matrix and mineral differs between bones at
different sites of the skeleton (see above). Such compositional
differences might alter the response and expression of proteins by the
osteoclasts [62] and osteoclast precursors [63]. After all, it has beenwell
established that extracellular matrix components affect cell behavior,
including expression of proteolytic enzymes (e.g. [62,64]). In an attempt
to study this in more detail we isolated osteoclasts from calvaria and
long bones and compared their activities. The osteoclasts were seeded
on their original and a different bone substrate and analyzed for the
enzymes used in resorption. Calvaria osteoclasts seeded on their own
substrate or on long bone slices used in both conditions MMPs and
cysteine proteinases. Similarly, long bone osteoclasts seeded on either
substrate used primarily cysteine proteinases. These ﬁndings indicate
that the bone substrate itself does not affect the phenotype of mature
osteoclasts, but does not exclude that there is an inﬂuence of substrate
during osteoclast generation.4.3. Different osteoclasts due to different precursors?
It is generally taken that osteoclast precursors reside in the circu-
lation and that these cells leave the blood system upon attraction by
chemokines locally produced by endothelial cells and/or bone lining
cells [65,66]. Numerous ﬁndings, including the classic studies of
Walker [67] who showed that osteopetrotic mice could be rescued by
temporary parabiosis (connecting the blood stream) with a normal
littermate, indicate that a mononuclear cell fraction present in the
peripheral blood has the capacity to differentiate into osteoclasts. This
feature, together with the availability of synthetic M-CSF and RANKL,
has revolutionized in vitro osteoclast formation studies from easily
accessible precursors in patients and volunteers. Despite this, con-
vincing evidence that in vivo the osteoclasts present at the different
bone sites always arise from blood-borne cells is not yet available.
Alternative sources of osteoclast precursors are the spleen, liver (in
very young animals) and the bone marrow. Spleen and bone marrow
are regularly used in osteoclast culture experiments, especially in
mouse studies.
Recently Richter et al. [68] showed that oc/ocmice can be cured by
intraperitoneal injection of retrovirally transduced osteoclast pre-
cursors expressing normal osteoclast V-ATPase, demonstrating that
precursors injected into the peritoneum ﬁnd their way to the blood
stream and subsequently into bone. However, this does still not
answer the question whether precursors generally home to marrow
spaces from where they are directed to the sites of resorption, or
whether they use the blood stream to directly extravasate at sites of
resorption. In addition, the questionwhether osteoclasts derived from
blood-borne cells differ from those generated from marrow cells has
not been investigated yet. Recent studies do show that various
mononuclear cell fractions isolated frommouse bonemarrow differ in
their capacity to form osteoclasts and their requirement for cytokines
[69,70]. It still has to be assessed, however, whether phenotypic
differences, such as enzyme proﬁles, cell size, or others as mentioned
above, exist between osteoclast populations derived from these
different mononuclear cell fractions.
Strong evidence for the existence of different subsets of osteoclast
precursors has recently come from studies in inﬂammatory conditions
[71]. It was demonstrated that osteoclasts can form from mature
dendritic cells through a process of transdifferentiation [71–75]. The
dendritic cell-derived osteoclasts were indistinguishable from osteo-
clasts derived from bloodmonocytes using awide range of phenotypic
markers. In vivo, it is now considered that dendritic cells may trans-
differentiate into osteoclasts due to interaction with cells producing
high levels of RANKL, such as T cells, stromal cells and/or osteoblasts,
conditions that may exist for example in the joint of patients with
rheumatoid arthritis. In addition there is evidence for the contribution
of B-cell-lineage cells to osteoclast formation [76]. Although this may
only occur under special circumstances, for example under the
inﬂuence of unusually high local levels of osteoclast-inducing factors
and in the presence of high numbers of B cells and osteoclast precur-
sors, such as in myeloma, it nevertheless indicates that different cell
lineages may contribute to the formation of osteoclasts.
In line with the notion that under inﬂammatory condi-
tions osteoclast precursors may differ is the study performed by
Nose et al. [77], who found that comparable numbers of osteoclast
precursors yielded higher numbers of osteoclasts if precursors were
from patients with rheumatoid arthritis, compared with precursors
from patients with osteoporosis.
5. Implications of osteoclast heterogeneity
The notion that theremay be bone-site-speciﬁc differences in bone
cells leading to local differences in bone remodeling has received
relatively little attention in the literature so far. Yet, we have shown
that there are abundant observations pointing to such differences in
763V. Everts et al. / Biochimica et Biophysica Acta 1792 (2009) 757–765osteoclasts. In addition we discussed the emerging evidence for site
speciﬁcity in bone lining cells/osteoblasts and osteocytes. Focusing on
osteoclasts, we would urge caution in the interpretation of studies
performed with cells from one source of precursors and extrapolating
results to all osteoclast populations. Bone phenotyping of whole
animal models of bone disease is often restricted to analyses of long
bones or vertebrae and, as we have shown above, this may not reveal
differential effects of gene knockout, or mutation, which may
speciﬁcally become apparent when comparing endochondral versus
intramembranous bones. Differences within bone, such as those
between trabecular and cortical bone will only be revealed upon
careful histological and immuno-phenotypical analysis. One may
question whether differences in osteoclasts are sufﬁciently important
towarrant such additional analyses. We should consider however that
novel osteoclast inhibitors are being developed, often using knowl-
edge of essential osteoclast gene products gained in the study of
osteopetrosis. One of these, a cathepsin K inhibitor, is in advanced
stages of clinical development [78]. Based on the evidence presented
above, we can be fairly sure that a cathepsin K inhibitor will primarily
reduce osteoclast activity in long bones and vertebrae, but far less in
the skull or jaw. Other inhibitors of osteoclast activity may have
different site speciﬁcity. This is not necessarily a problem, but may
in fact be seen as a new challenge and an opportunity. Studies are
ongoing to understand the site-speciﬁc effects of bisphosphonates on
the skeleton. When coupled with the notion of cellular site speciﬁcity,
such information may lead to novel, rational drug treatments, even
with drugs, or combinations of drugs, already licensed. In a similar
way, the notion that anabolic PTH treatment does not beneﬁt all bones
(or bone sites) alike [79] clearly points to differences in the osteoblast
compartment and urges caution with generalization of treatment
effects observed in one site only to the whole skeleton. We expect
there is a lot of additional data on bone-site speciﬁcity of treatment
effects and cellular responses already collected, but not necessa-
rily reported in the literature as this data may have been seen as
“erroneous results”. We would suggest that cellular heterogeneity in
bone is more likely than not. Clearly this is an area that requires
further careful study to fully exploit therapeutically the immense
advances in knowledge of osteoclast biology gained from the study of
rare osteoclast diseases such as osteopetrosis.
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